---
title: "Scotiabank maintains Sector Outperform rating on Amgen, $500 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300455380.md"
description: "Scotiabank maintains a Sector Outperform rating on Amgen with a $500 price target, implying 19.6% upside from the September 28 close of $418.13. The bank cites Amgen's robust product portfolio and strategic acquisitions in oncology and rare diseases as key growth drivers. Additionally, positive financial outlooks, including expected high-single-digit R&D expenditure growth, support the investment thesis."
datetime: "2026-09-29T14:56:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300455380.md)
  - [en](https://longbridge.com/en/news/300455380.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300455380.md)
generator: "portal-rs"
---

# Scotiabank maintains Sector Outperform rating on Amgen, $500 price target

Scotiabank maintained their Sector Outperform rating on Amgen's stock with a price target of $500.00.

The price target implies an upside of 19.6% from the Sep 28 close of $418.13.

**Key takeaways from the analyst note**

**Strong Product Portfolio and Strategic Acquisitions**: Amgen has a diverse and robust product portfolio that includes leading therapies for various serious diseases, which positions the company well for sustained growth. Recent strategic acquisitions, such as Horizon and Onyx Pharmaceuticals, have strengthened its offerings in oncology and rare diseases, further enhancing its market potential.

**Positive Financial Outlook**: Scotiabank's confidence in Amgen is reflected in its expectation of high-single-digit year-over-year growth in non-GAAP R&D expenditures, indicating a commitment to innovation and development. This financial outlook supports the firm's growth trajectory and justifies the Sector Outperform rating.

Explore more price target data and ratings for Amgen on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [BNS.US](https://longbridge.com/en/quote/BNS.US.md)

## Related News & Research

- [How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story](https://longbridge.com/en/news/300175029.md)
- [Amgen reports a Phase 3 win with Sjögren’s drug candidate](https://longbridge.com/en/news/300046755.md)
- [Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data](https://longbridge.com/en/news/299801248.md)
- [Amgen Announces Positive Topline Phase 3 Results For Dazodalibep In Sjogren's Disease](https://longbridge.com/en/news/299775087.md)
- [Amgen's autoimmune drug succeeds in late-stage trial](https://longbridge.com/en/news/299770733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**